These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8099528)
1. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588 [TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Hung MC; Zhang X; Yan DH; Zhang HZ; He GP; Zhang TQ; Shi DR Cancer Lett; 1992 Jan; 61(2):95-103. PubMed ID: 1346099 [TBL] [Abstract][Full Text] [Related]
5. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration. Cohen JA; Yachnis AT; Arai M; Davis JG; Scherer SS J Neurosci Res; 1992 Apr; 31(4):622-34. PubMed ID: 1374476 [TBL] [Abstract][Full Text] [Related]
6. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Volm M; Kästel M; Mattern J; Efferth T Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529 [TBL] [Abstract][Full Text] [Related]
7. Frequency of Her2/Neu Protein Expression in Ovarian Epithelial Cancers. Jafri A; Rizvi S J Coll Physicians Surg Pak; 2017 Sep; 27(9):544-546. PubMed ID: 29017668 [TBL] [Abstract][Full Text] [Related]
8. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Yu D; Wolf JK; Scanlon M; Price JE; Hung MC Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034 [TBL] [Abstract][Full Text] [Related]
9. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Hou L; Shi D; Tu SM; Zhang HZ; Hung MC; Ling D Cancer Lett; 1992 Aug; 65(3):215-20. PubMed ID: 1355405 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347 [TBL] [Abstract][Full Text] [Related]
11. Clinical use of serum c-erbB-2 in patients with ovarian masses. Cheung TH; Wong YF; Chung TK; Maimonis P; Chang AM Gynecol Obstet Invest; 1999; 48(2):133-7. PubMed ID: 10461006 [TBL] [Abstract][Full Text] [Related]
12. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Slamon DJ; Godolphin W; Jones LA; Holt JA; Wong SG; Keith DE; Levin WJ; Stuart SG; Udove J; Ullrich A Science; 1989 May; 244(4905):707-12. PubMed ID: 2470152 [TBL] [Abstract][Full Text] [Related]
13. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. Wu JT; Astill ME; Zhang P J Clin Lab Anal; 1993; 7(1):31-40. PubMed ID: 8093903 [TBL] [Abstract][Full Text] [Related]
14. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577 [TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
16. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607 [TBL] [Abstract][Full Text] [Related]
18. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients]. Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438 [TBL] [Abstract][Full Text] [Related]
19. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Kath R; Höffken K; Otte C; Metz K; Scheulen ME; Hülskamp F; Seeber S Ann Oncol; 1993 Aug; 4(7):585-90. PubMed ID: 8103351 [TBL] [Abstract][Full Text] [Related]
20. Rare expression of the c-erbB-2 oncoprotein in salivary gland tumors: an immunohistochemical study. Shrestha P; Huang JW; Tsuji T; Shinozaki F; Maeda K; Sasaki K; Ueno K; Yamada K; Mori M J Oral Pathol Med; 1992 Nov; 21(10):477-80. PubMed ID: 1361005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]